Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

PMF and SMF have different but not specific molecular profiles and different prognosis depending on the molecular profile. This may be due to differences in disease history. Combining mutations and existing scores should improve prognosis assessment.